Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Willamette Valley Cancer Center
mi
from
Eugene, OR
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Willamette Valley Cancer Center
mi
from
Eugene, OR
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Virginia Oncology Assoc.
mi
from
Norfolk, VA
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Virginia Oncology Assoc.
mi
from
Norfolk, VA
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Northwest Cancer Specialists at Vancouver Cancer Center
mi
from
Vancouver, WA
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Northwest Cancer Specialists at Vancouver Cancer Center
mi
from
Vancouver, WA
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Yakima Valley Memorial
mi
from
Yakima, WA
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Yakima Valley Memorial
mi
from
Yakima, WA
Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma
Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma
Status: Archived
Univ of Minnesota
mi
from
Minneapolis, MN
Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma
Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Univ of Minnesota
mi
from
Minneapolis, MN
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Boca Raton Clinical Research Associates
mi
from
Boca Raton, FL
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Boca Raton Clinical Research Associates
mi
from
Boca Raton, FL
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Kellogg Cancer Care Center
mi
from
Highland Park, IL
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Kellogg Cancer Care Center
mi
from
Highland Park, IL
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Boston Med Center
mi
from
Boston, MA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Boston Med Center
mi
from
Boston, MA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Henry Ford Hospital
mi
from
Detroit, MI
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
mi
from
Detroit, MI
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Washington University
mi
from
St. Louis, MO
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Morristown Memorial Hospital
mi
from
Morristown, NJ
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Morristown Memorial Hospital
mi
from
Morristown, NJ
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Bronx River Medical Associates, PC
mi
from
Bronx, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Bronx River Medical Associates, PC
mi
from
Bronx, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Erie County Medical Center
mi
from
Buffalo, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Erie County Medical Center
mi
from
Buffalo, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
State University of New York - Erie Country Medical Center
mi
from
Buffalo, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
State University of New York - Erie Country Medical Center
mi
from
Buffalo, NY
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Hematology Associates
mi
from
Bedford, OH
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Hematology Associates
mi
from
Bedford, OH
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
ACORN - The West Clinic
mi
from
Memphis, TN
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
ACORN - The West Clinic
mi
from
Memphis, TN
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
VCU Medical Center
mi
from
Richmond, VA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
VCU Medical Center
mi
from
Richmond, VA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Cascade Cancer Center
mi
from
Kirkland, WA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Cascade Cancer Center
mi
from
Kirkland, WA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
University of Nebrasaka Medical Center
mi
from
Omaha, NE
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
University of Nebrasaka Medical Center
mi
from
Omaha, NE
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
M. D. Anderson Cancer Center
mi
from
Orlando, FL
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
mi
from
Orlando, FL
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
A Phase I Study of Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
Status: Archived
Nevada Cancer Institute
mi
from
Las Vegas, NV
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
A Phase I Study of Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
Status: Archived
Updated: 1/1/1970
Nevada Cancer Institute
mi
from
Las Vegas, NV
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Status: Archived
Children's Hospital
mi
from
Pittsburgh, PA
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Status: Archived
Updated: 1/1/1970
Children's Hospital
mi
from
Pittsburgh, PA
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Status: Archived
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Status: Archived
Updated: 1/1/1970
Children's Nutrition Research Center, Baylor College of Medicine
mi
from
Houston, TX
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
AIDS Associated Malignancies Clinical Trials Consortium
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
AIDS Associated Malignancies Clinical Trials Consortium
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Siteman Cancer Center
mi
from
St. Louis, MO
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Siteman Cancer Center
mi
from
St. Louis, MO
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Virginia Mason Medical Center
mi
from
Seattle, WA
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy
A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy
Status: Archived
Updated: 1/1/1970
Virginia Mason Medical Center
mi
from
Seattle, WA
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Umbilical Cord Blood Transplant for Hematological Malignancies
A Phase 1 Dose Escalation Study of Infusion of ex Vivo cd3/cd28 Costimulated Umbilical Cord Blood-derived t Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Umbilical Cord Blood Transplant for Hematological Malignancies
A Phase 1 Dose Escalation Study of Infusion of ex Vivo cd3/cd28 Costimulated Umbilical Cord Blood-derived t Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Archived
Winship Cancer Institute of Emory University
mi
from
Egleston, GA
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Archived
Updated: 1/1/1970
Winship Cancer Institute of Emory University
mi
from
Egleston, GA